Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Grant or award Director acquired 5,967 shares (grant or award)
  2. 4 Grant or award Director acquired 5,967 shares (grant or award)
  3. 4 Grant or award Director acquired 5,967 shares (grant or award)
  4. 4 Grant or award Director acquired 5,967 shares (grant or award)
  5. 8-K Event Shareholder vote results
  6. 4 Planned sale Director sold 1,674 shares at $20.39 ($34,133)
  7. 10-Q Report Quarterly Report
  8. 8-K Event Results of operations
  9. ARS Other Annual Report to Security Holders
  10. DEFA14A Proxy Proxy Materials
  11. DEF 14A Proxy Proxy Statement
  12. 4 Planned sale Director sold 1,666 shares at $18.29 ($30,471)
  13. 144 Insider Sale of Securities
  14. 4 Planned sale Director sold 92,500 shares at $20.50 ($1,896,250)
  15. 144 Insider Sale of Securities
  16. 4 Gift President and CEO gave 40,000 shares (gift)
  17. S-3ASR Offering Registration Statement
  18. 4 Planned sale Director sold 1,666 shares at $20.10 ($33,487)
  19. D Other Notice of Sales of Unregistered Securities
  20. S-8 Other Securities Offered to Employees in Benefit Plans

Page 10 of 40 · 789 filings